Fulcrum therapeutics to participate in upcoming december conferences

Cambridge, mass., nov. 26, 2024 (globe newswire) -- fulcrum therapeutics, inc.® (the “company”) (nasdaq: fulc), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in the following conferences:
FULC Ratings Summary
FULC Quant Ranking